{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T21:59:53Z","timestamp":1675893593665},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s10165-009-0244-3","type":"journal-article","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T10:44:36Z","timestamp":1257504276000},"page":"183-187","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of cytokine production patterns of peripheral blood mononuclear cells from a rheumatoid arthritis patient successfully treated with rituximab"],"prefix":"10.1093","volume":"20","author":[{"given":"Akinori","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Asanuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,11,7]]},"reference":[{"key":"244_CR1","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105\u201310.","journal-title":"Lancet"},{"key":"244_CR2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141\u20137.","journal-title":"N Engl J Med"},{"key":"244_CR3","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:1761\u20139.","journal-title":"Arthritis Rheum"},{"key":"244_CR4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987\u201397.","journal-title":"Lancet"},{"key":"244_CR5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865\u201376.","journal-title":"Ann Intern Med"},{"key":"244_CR6","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Kaine JL, Lowenstein MB, Giudice JD, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:2652\u201361.","journal-title":"Arthritis Rheum"},{"key":"244_CR7","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572\u201381.","journal-title":"N Engl J Med"},{"key":"244_CR8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","volume":"56","author":"A Finckh","year":"2007","unstructured":"Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417\u201323.","journal-title":"Arthritis Rheum"},{"key":"244_CR9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2332\/allergolint.R-07-158","volume":"57","author":"K Sato","year":"2008","unstructured":"Sato K. Th17 cells and rheumatoid arthritis\u2013\u2013from the standpoint of osteoclast differentiation. Allergol Int. 2008;57:109\u201314.","journal-title":"Allergol Int"},{"key":"244_CR10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","volume":"25","author":"CT Weaver","year":"2007","unstructured":"Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821\u201352.","journal-title":"Annu Rev Immunol"},{"key":"244_CR11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594\u2013602.","journal-title":"N Engl J Med"},{"key":"244_CR12","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146\u201354.","journal-title":"Arthritis Rheum"},{"key":"244_CR13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.1780040105","volume":"4","author":"J Harris","year":"1961","unstructured":"Harris J, Vaughan JH. Transfusion studies in rheumatoid arthritis. Arthritis Rheum. 1961;4:47\u201355.","journal-title":"Arthritis Rheum"},{"key":"244_CR14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793\u2013806.","journal-title":"Arthritis Rheum"},{"key":"244_CR15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.autrev.2007.03.006","volume":"7","author":"A Manzo","year":"2007","unstructured":"Manzo A, Pitzalis C. Lymphoid tissue reactions in rheumatoid arthritis. Autoimmun Rev. 2007;7:30\u20134.","journal-title":"Autoimmun Rev"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-009-0244-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:27:21Z","timestamp":1646843241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-009-0244-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,7]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["244"],"URL":"https:\/\/doi.org\/10.1007\/s10165-009-0244-3","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,7]]}}}